Deans' stroke musings: Prognostic assessment of acute ischemic stroke by systemic immune-inflammatory index: a comprehensive meta-analysis of multidimensional outcomes

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, October 28, 2025

Prognostic assessment of acute ischemic stroke by systemic immune-inflammatory index: a comprehensive meta-analysis of multidimensional outcomes

Predicting failure to recover IS ABSOLUTELY FUCKING USELESS! Does no one in stroke have any brains at all?

Prognostic assessment of acute ischemic stroke by systemic immune-inflammatory index: a comprehensive meta-analysis of multidimensional outcomes

Yanhong Jiang¹

Yifan Cui¹

Xiaojie Hu²

Jiaying Lian³

Xueying Qin⁴

Xingchen Wang^1,2^*

Xuran Ma¹^*

¹The Second Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China
²Department of Neurology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
³Department of Neurology, Quzhou Traditional Chinese Medicine Hospital, Quzhou, China
⁴The First Clinical Medical College, Beijing University of Traditional Chinese Medicine, Beijing, China

Introduction: Our study aimed to quantify the predictive ability of the Systemic Immune-inflammatory Index (SII) for predicting the prognosis and multidimensional complications in acute ischemic stroke (AIS) patients. The primary outcome was poor prognosis, and secondary outcomes included mortality, severity, hemorrhagic transformation/symptomatic intracerebral hemorrhage, stroke-associated pneumonia/poststroke pneumonia, early neurological deterioration, post-stroke depression, progression or recurrence, and other adverse outcomes.

Methods: We searched 15 databases from their establishment to 13 October 2024 and selected cohort or case-control analyses that analyzed the association of continuous or categorized SII as exposures with the above adverse outcomes of AIS populations.

Results: The results showed that 78 studies with 40,682 participants were included in meta-analyses. Continuous SII values were significantly higher in poor prognosis groups than in controls (SMD = 248.13, 95% CI: 198.77 to 297.50; p = 0.000). Poor prognosis incidences rose with higher continuous SII values (OR = 1.004, 95% CI: 1.002 to 1.005; p = 0.000). More patients in High SII groups had poor prognosis (RR = 1.95, 95% CI: 1.66 to 2.28; p = 0.000). The risk of poor prognosis was higher in the high SII groups, though this was not statistically significant (OR = 1.007, 95% CI: 0.998 to 1.015; p = 0.120).

Discussion: In conclusion, our study found that continuous SII and high SII were associated with poor prognosis of AIS and various complications. Given the accessibility and low cost of SII, integrating it into prognostic scores merits further research for better clinical choices.

Systematic review registration: PROSPERO (CRD42024586414), https://www.crd.york.ac.uk/PROSPERO/view/CRD42024586414.